News

Media

Conferences

Publications

Clinical

Events

Resources

Enhancing Access to Lipid-Lowering Therapies and Optimizing Cholesterol Management in Very High-Risk Patients with ASCVD : Episode 4

Opinion

Video

April 30, 2024

Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.

EP: 1.How Often Do Patients with ASCVD Achieve Target LDL-C?

EP: 2.Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

EP: 3.Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

EP: 4.Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

EP: 5.Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

EP: 6.Clinical Efficacy of Non-Statin Treatment Options in ASCVD

EP: 7.Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

EP: 8.Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

EP: 9.The Role of Pharmacists in Treating Very High-Risk ASCVD

EP: 10.Valuable Metrics and Improving Adherence in Patients With ASCVD

EP: 11.Successful Collaborative Care Strategies for Pharmacists

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos

5 experts in this video

Related Content

Related Content

Consent Preferences

Clinical Forums

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.